Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRICAL: CMV and TB Treatment in HIV-infected Infants with Severe Pneumonia
NCT03915366Phase 3Completed
- Sponsor
- Hospital Universitario 12 de Octubre
- Start
- Mar 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of valganciclovir, rifampicin, isoniazid, pyrazinamide, ethambutol in cytomegalovirus infection (CMV), Tuberculosis (TB), sponsored by Hospital Universitario 12 de Octubre. Started Mar 2020; status: completed.
02
Drugs
valganciclovirrifampicinisoniazidpyrazinamideethambutol
03
Conditions
cytomegalovirus infection (CMV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03915366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915366.